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Abstract
Objectives—Several outbreaks of serogroup B meningococcal disease have occurred among 
university students in recent years. In the setting of high coverage of the quadrivalent 
meningococcal conjugate vaccine and prior to widespread use of serogroup B meningococcal 
vaccines among adolescents, we conducted surveys to characterize the prevalence and molecular 
characteristics of meningococcal carriage among university students.
Methods—Two cross-sectional oropharyngeal carriage surveys were conducted among 
undergraduates at a Rhode Island university. Isolates were characterized using slide agglutination, 
real-time polymerase chain reaction (rt-PCR), and whole genome sequencing. Adjusted prevalence 
ratios and 95% confidence intervals were calculated using Poisson regression to determine risk 
factors for carriage.
Results—A total of 1837 oropharyngeal specimens were obtained from 1478 unique 
participants. Overall carriage prevalence was 12.7–14.6% during the two survey rounds, with 1.8–
2.6% for capsular genotype B, 0.9–1.0% for capsular genotypes C, W, or Y, and 9.9–10.8% for 
nongroupable strains by rt-PCR. Meningococcal carriage was associated with being male, 
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smoking, party or club attendance, recent antibiotic use (inverse correlation), and recent 
respiratory infections.
Conclusions—In this university setting, the majority of meningococcal carriage was due to 
nongroupable strains, followed by serogroup B. Further evaluation is needed to understand the 
dynamics of serogroup B carriage and disease among university students.
Keywords
Meningococcal disease; Carriage; Meningococcal vaccines; Neisseria meningitidis; 
Meningococcal infections
1. Background
Meningococcal disease is a rare but serious illness resulting in high rates of morbidity and 
mortality. Transmission of the causative organism, Neisseria meningitidis, occurs through 
close contact with respiratory secretions, resulting primarily in asymptomatic 
nasopharyngeal carriage and rarely, invasive meningococcal disease. Adolescents and young 
adults in the United States are at increased risk of meningococcal carriage and disease due to 
increased social mixing, crowded living conditions, smoking, and other behaviors [1–4].
The Advisory Committee on Immunization Practices (ACIP) recommends routine 
vaccination of adolescents with a quadrivalent meningococcal conjugate vaccine 
(MenACWY) at age 11 or 12 years, with a booster dose at age 16 years to sustain protection 
through early adulthood [5]. Like other conjugate vaccines, MenACWY (MenACWY-D 
[Menactra®, Sanofi Pasteur [6]], MenACWY-CRM [Menveo®, Novartis [7]]) may reduce 
acquisition of nasopharyngeal carriage, and thus transmission, when high coverage is 
achieved, though data are limited [8–10]. Since implementation of the adolescent 
MenACWY program in 2005, coverage with at least one dose of MenACWY among 13–17 
year olds reached 81.3% in 2015 [11]. Incidence of serogroup C and Y meningococcal 
disease among adolescents has subsequently declined, with serogroup B Neisseria 
meningitidis becoming the leading cause of meningococcal disease in this age group [12].
In 2014 and 2015, two serogroup B meningococcal (MenB) vaccines, MenB-4C (Bexsero®, 
GlaxoSmithKline) and MenB-FHbp (Trumenba®, Pfizer), were licensed for use in the 
United States [13,14]. In 2015, ACIP recommended that adolescents and young adults aged 
16–23 years may be vaccinated with a MenB vaccine based on individual clinical discretion 
[15]. MenB vaccines are routinely recommended for certain persons aged ≥ 10 years at 
increased risk of serogroup B meningococcal disease, including during an outbreak of 
serogroup B meningococcal disease [16]. The impact of MenB vaccines on carriage remains 
under investigation [8,17,18].
In the context of high adolescent MenACWY coverage and low meningococcal disease 
incidence, with a predominance of outbreaks and sporadic disease now due to serogroup B, 
there is little recent data on the prevalence and serogroup distribution of carried N. 
meningitidis among U.S. university students. We conducted a carriage evaluation among 
undergraduate students at a Rhode Island university in a non-outbreak setting prior to 
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widespread availability of MenB vaccines to determine prevalence and molecular 
characteristics of meningococcal carriage and identify risk factors for carriage in this 
population.
2. Materials and methods
2.1. Study design
Two cross-sectional oropharyngeal carriage surveys were conducted in March (round 1) and 
April (round 2) 2015 at a Rhode Island university (‘University A’), with participants 
recruited by convenience sampling among an undergraduate student population of 6320. All 
undergraduate students aged 18 years or older were eligible for voluntary participation and 
were recruited through emails and printed materials. University A is in the same city as 
Providence college, which experienced an outbreak of serogroup B meningococcal disease, 
with two cases reported among an undergraduate population of 4500 students, in February 
2015 [19]. Though not assessed formally, university officials speculate there is minimal 
interaction between students at the two universities, and no cases of meningococcal disease 
were reported at University A.
2.2. Data and specimen collection
Enrollment and specimen collection were performed in common areas of the university, such 
as the student center and adjacent to a large cafeteria. Upon enrollment, all participants 
provided written informed consent and completed a self-administered questionnaire 
consisting of demographic information and potential factors associated with meningococcal 
carriage, including university year, living arrangements, history of tobacco and marijuana 
use, attendance at parties and bars, upper respiratory infection in the past 14 days, and 
history of antibiotic use in the past 30 days. MenACWY and MenB vaccination status was 
obtained through abstraction of student medical records at the university health center, 
where vaccination records are submitted upon university matriculation and maintained 
thereafter. As no MenB vaccine doses were documented in participant medical records and 
the carriage evaluation took place within five months of U.S. licensure of the first MenB 
vaccine and prior to ACIP recommendations for use of MenB vaccines among healthy 
adolescents and young adults, we assumed all participants to be unvaccinated with MenB.
Oropharyngeal swabs from each tonsillar pillar and the posterior pharynx were collected by 
trained personnel using bifurcated swabs. One swab was directly inoculated onto Modified 
Thayer–Martin (MTM) media (BD BBL, Sparks, MD) for culture. Inoculated media were 
stored in CO2-enriched Mitsubishi boxes at room temperature along with a positive control 
plate inoculated with N. lactamica. Inoculated plates and specimens were transported to the 
Rhode Island State Health Department Laboratory for primary testing with a maximum 
delay of four hours.
2.3. Laboratory methods
Inoculated culture plates were streaked, incubated at 37 °C (5% CO2), and examined for 
bacterial growth after 24, 48, and 72 h. Colonies with typical Neisserial morphology 
underwent Gram staining and were sub-cultured onto blood and/or chocolate agar plates. A 
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single colony per participant per round was selected for further characterization. At a species 
level, N. meningitidis was identified using Gram stain, oxidase test (Hardy Diagnostics; 
Santa Maria, CA), API NH strip (bioMerieux; Durham, NC), and sodC PCR assay [20,21]. 
Once confirmed as N. meningitidis, serogroup was determined by slide agglutination and 
capsular genotype by real-time PCR (rt-PCR). Expression of the capsular polysaccharide 
was determined by slide agglutination for serogroups A, B, C, E, W, X, Y, and Z (BD 
DIFCO; Franklin Lakes, NJ; and Thermo Scientific Remel; Waltham, MA). rt-PCR was 
used to detect the capsule biosynthesis genes specific for serogroups A, B, C, W, X, and Y 
[22]. An isolate was defined as nongroupable by slide agglutination when it autoagglutinated 
or did not agglutinate. As previously described, carriage isolates are commonly 
nongroupable phenotypically due to a low level or absence of capsule gene expression, while 
these isolates may still contain the capsule biosynthesis genes as detected by rt-PCR [23,24]; 
because of this, nongroupable genotype was independently defined by rt-PCR as no 
amplification in any serogroup-specific PCR assay.
For further characterization of serogroup B isolates and other isolates with discrepant results 
(e.g., discrepant NH strip and sodC results), genomic DNA was prepared for whole genome 
sequencing (WGS) on Illumina MiSeq platform (250 × 250 cycle paired-end sequencing kit; 
San Diego, CA) using 5 Prime ArchivePure DNA Purification kit (Gaithersburg, MD), 
Ampure (Beckman Coulter Inc.; Indianapolis, IN), and dual-index NEBNext Ultra 
sequencing libraries (New England Biolabs Inc.; Ipswich, MA). Published primer sequences 
were used to extract the seven meningococcal MLST house-keeping genes, fetA, and porA 
from CLC (v8.5.1; Qiagen; Waltham, MA) assembled WGS data [25]. After running 
extracted sequences through BLAST against the Neisseria PubMLST database, MLST 
sequencing type (ST) and clonal complex (CC), outer membrane (FetA and PorA) types and 
vaccine antigens (FHbp, NhbA, and NadA) were determined [26,27]. As previously 
described, a combination of the three nomenclature systems was used for FHbp type 
(Oxford numeric identifier followed by Pfizer subfamily and Novartis variant) [28].
2.4. Data analysis
Descriptive analyses were conducted for demographic and risk factor information. 
Significant differences (P < .05) by round were assessed using a chi-square test for 
categorical variables and the Wilcoxon-Mann-Whitney test for continuous variables. The 
prevalence of meningococcal carriage overall and by serogroup and capsular genotype was 
determined for each survey round. To determine factors associated with overall carriage, 
prevalence ratios were calculated with bivariate Poisson regression analyses using 
generalized estimating equations and an exchangeable correlation structure to account for 
correlation of observations from individual participants across rounds. Collinearity and 
interactions were assessed, given the potential relatedness of several variables (e.g., smoking 
and partying, upper respiratory tract infection and use of antibiotics). Factors found to be 
significantly associated with carriage at P < .1 were included in a multivariable model. 
Factors that remained significant at P < .05 were considered to be independent predictors of 
meningococcal carriage. All data analyses were conducted using SAS 9.3 (SAS Institute, 
Cary, North Carolina).
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2.5. Ethical review
This investigation was determined to be a public health evaluation and designated as non-
research by the Centers for Disease Control and Prevention Human Research Protection 
Office, the chair of the Rhode Island Department of Health Institutional Review Board 
(IRB), and the chair of University A IRB, and therefore did not require full IRB review. 
Participation was voluntary and written informed consent was obtained from all participants 
by trained survey staff. Participants received a $5 retail gift card for completion of the 
survey.
3. Results
In total, 1845 participants were enrolled in two carriage evaluation rounds. Among these, 8 
were excluded due to a missing questionnaire or specimen, or duplicate specimen 
submission. Thus, 1837 oropharyngeal specimens, including 1076 (58.6%) specimens in 
round one and 761 (41.4%) in round two, were collected from 1478 unique participants. 
Three hundred fifty-nine participants were enrolled in both rounds. Characteristics of 
participants are shown in Table 1.
Among 1837 oropharyngeal specimens collected, 248 meningococcal isolates were 
recovered during the two survey rounds, including 137 of 1076 (12.7%) specimens in round 
one and 111 of 761 (14.6%) specimens in round two (Table 2). By slide agglutination, 0.7% 
of participants in each round carried meningococci that expressed the serogroup B capsule. 
By rt-PCR, 1.8% and 2.6% of participants carried capsular genotype B N. meningitidis in 
rounds one and two, respectively. Total carriage of N. meningitidis serogroups or capsular 
genotypes C, W, or Y ranged from 0.0 to 0.2% by slide agglutination and 0.9–1.0% by rt-
PCR in the two rounds. Among participants carrying N. meningitidis, the majority carried 
nongroupable strains: 11.6–13.8% by slide agglutination and 9.9–10.8% by rt-PCR.
Of the 359 participants that took part in both carriage survey rounds, 45 participants (12.5%) 
were identified as carriers during at least one of the rounds and 29 (8.1%) were carriers in 
both rounds. From round one, 33 participants (9.2%) were identified as carriers; all isolates 
from these participants were nongroupable by slide agglutination, and the majority were also 
nongroupable by rt-PCR (n = 27, 81.8%), with 6 capsular genotype B isolates identified. In 
round two, a total of 42 (11.4%) participants were found to be carriers, including 29 carriers 
from round one that remained carriers in round two: 28 (96.6%) remained nongroupable by 
slide agglutination and one (3.4%) participant was found to carry serogroup B. The majority 
of nongroupable isolates by slide agglutination (n = 35, 83.3%) were also predominantly 
nongroupable by rt-PCR, with seven (16.7%) capsular genotype B isolates identified. 
Twelve additional new carriers were identified in round two and all acquired nongroupable 
N. meningitidis by slide agglutination. Of these isolates, six (50%) were capsular genotype 
B by rt-PCR and six (50%) were also nongroupable by rt-PCR.
Among 39 isolates identified as capsular genotype B by rt-PCR, 23 sequence types (ST) 
belonging to 9 clonal complexes (CC) were identified, including one new ST (12750). 
(Table 3). The most common CCs detected were CC41/44 Lineage 3 (n = 8), CC32/ET-5 (n 
= 10) and CC35 (n = 9). ST-9069, the strain associated with the outbreak at Providence 
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College, was not identified among meningococcal carriers at University A. Further 
characterization of capsular genotype B isolates for PorA, FetA, FHbp, and NhbA are 
described in Table 3.
In bivariate Poisson regression analysis, an increased risk of carriage due to any serogroup 
or capsular genotype was associated with participation in round two of the evaluation; being 
male; going out to bars/parties at least one time per week on average; smoking tobacco or 
marijuana in the past 30 days; being exposed to second hand smoke in the last 30 days; and 
having had an upper respiratory tract infection in the last 14 days (Table 4). Residing in a 
residence hall and antibiotic use in the last 30 days were associated with reduced risk of 
carriage. Age, university class year, and MenACWY vaccine receipt were not associated 
with carriage. Collinearity and interactions were assessed but no significant associations 
were found.
In a multivariable analysis, participation in round two (aPR 1.20 [95% CI 1.01–1.42]), male 
sex (aPR 1.66 [95% CI: 1.29–2.14]), going out to bars/parties at least one time per week on 
average (aPR 2.03 [95% CI: 1.52–2.72]), tobacco use in the past 30 days (aPR 1.53 [95% 
CI:1.21–1.94]), and an upper respiratory tract infection in the past 14 days (aPR 1.23 [95% 
CI: 1.001–1.51]) remained independently associated with carriage. Antibiotic use in the last 
30 days continued to be inversely associated with carriage (aPR 0.42 [95% CI: 0.27–0.65]) 
(Table 4).
4. Discussion
Although rates of meningococcal disease in the United States are currently at historic lows, 
cases and outbreaks of meningococcal disease continue to occur among university students 
[29]. In our evaluation at a university with high MenACWY vaccine coverage, prior to 
widespread MenB vaccine availability, we found that prevalence of N. meningitidis carriage 
was 12.7–14.6%. This prevalence is higher than the 3.2–8% reported in recent carriage 
evaluations among U.S. high school and university-aged persons [3,30,31]. The low 
prevalence of encapsulated isolates, with few serogroup B and a near-absence of serogroups 
C and Y N. meningitidis, is consistent with the epidemiology of invasive meningococcal 
disease in this age group, which is characterized by overall low disease incidence, a 
predominance of cases due to serogroup B, and declines in the proportion of cases due to 
serogroups C and Y [32].
This evaluation, performed in a university population without recent meningococcal disease 
cases, provides an opportunity to compare characteristics of meningococcal carriage with 
those described at two other universities (neighboring Providence College, and a large, 
public university in Oregon) that experienced serogroup B meningococcal disease outbreaks 
and implemented three-dose MenB-FHbp vaccination campaigns during similar time periods 
in 2015–2016. Overall carriage and serogroup B-specific N. meningitidis carriage 
prevalence in the University A population was roughly half of that observed at Providence 
College, where overall carriage rates were 20–24% and capsular genotype B carriage was 
4% by rt-PCR. Carriage in University A students was similar to the 11–17% overall carriage 
and 1–2% capsular genotype B-specific carriage observed at the university in Oregon 
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[17,18]. While these three universities differ in terms of size, university type (public or 
private), region of the country, epidemiologic situation, and MenB vaccination status, 
carriage in all three was characterized by a predominance of nongroupable meningococcal 
isolates and relatively low prevalence of capsular genotype B meningococcal carriage. 
Similar to these other two universities, and consistent with previous reports in the literature, 
meningococcal carriage at University A was associated with being male, smoking, attending 
parties, bars, or clubs, using antibiotic recently (inverse correlation), and having a recent 
upper respiratory tract infection [33–37].
Prevalence of capsular genotype B meningococcal carriage remained stable across the two 
survey rounds in our evaluation, and the strain causing the outbreak at Providence College 
(ST-9069) was not recovered from our university population. The few capsular genotype B 
isolates that were recovered in our evaluation displayed high genetic diversity. Of the clonal 
complexes identified among the capsular genotype B isolates, CC32/ET-5, CC35, and 
CC41/44 lineage 3 were the most common. These hyper-invasive lineages, found globally 
from carriage and invasive isolates, were previously associated with university outbreaks in 
California, New Jersey, and Oregon [24]. These hyper-invasive lineages, along with other 
identified clonal complexes (CC162, CC213, CC865, CC4821), have also been reported in 
the United States and Europe as carriage isolates in previous evaluations [3,23,30,38,39].
The detected vaccine antigen types (FHbp, NhbA, and NadA) in our evaluation were also 
observed among sporadic and carriage isolates globally and in the United States. [23,28,40]. 
Among serogroup B isolates, we found that FHbp variant A/v2–3 predominated, NadA was 
unrepresented, and all isolates had an NhbA antigen type. Seventeen percent of serogroup B 
carriage isolates possessed one or more specific MenB vaccine subvariants (2 isolates with 
FHbp subvariant 1/NadA-1.1, 4 with NhbA subvariant p0002, and 1 with FHbp subvariant 
45) included in either the MenB-4C or the MenB-FHbp vaccine. The remaining 83% of 
serogroup B isolates, with subvariants not included in the vaccines, may still be covered by 
the vaccines through cross-reactivity [41]. However, implications of this potential vaccine 
coverage are uncertain, as we did not evaluate the level of gene expression and isolate 
susceptibility to antibodies induced by vaccine antigens [28,40].
The potential impact of MenB vaccines on serogroup B meningococcal carriage remains 
unclear, with one U.K. evaluation suggesting that MenB-4C has little to no effect on 
reducing acquisition of meningococcal carriage [8]. Furthermore, recent evaluations at two 
U.S. universities suggest that vaccination with MenB-FHbp during serogroup B outbreaks 
does not rapidly reduce meningococcal carriage or reduce acquisition of meningococcal 
carriage following three vaccine doses [17,18]. Though we did not detect differences in 
carriage prevalence by MenACWY vaccination status, the recovery of few serogroup C or Y 
isolates and no serogroup W isolates among a highly-vaccinated university population 
suggests a potential impact of MenACWY on meningococcal carriage in U.S. university 
students. However, impact of MenACWY on meningococcal carriage in this population 
remains poorly understood, with a recent evaluation in the United Kingdom demonstrating a 
rise in serogroup W carriage despite 71% MenACWY vaccination coverage in university 
students [42].
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In conclusion, results from our evaluation demonstrate that in the setting of high MenACWY 
vaccine coverage among a university population, the majority of meningococcal carriage is 
due to nongroupable strains, with low serogroup B carriage prevalence and a near absence of 
serogroups covered by the quadrivalent meningococcal conjugate vaccine. However, as 
serogroup B meningococcal disease outbreaks remain a public health concern at U.S. 
universities, these findings highlight the need to further evaluate serogroup B carriage and 
disease dynamics, in order to guide routine vaccination policy and outbreak response 
measures in this population.
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Table 2
Prevalence of N. meningitidis carriage overall and by serogroup (slide agglutination) and capsular genotype 
(real-time polymerase chain reaction) among participants at University A, by survey round, March–April 
2015.
Carriage Round One (N = 1076) Round Two (N = 761)
N % N %
N. meningitidis carriage 137 12.7 111 14.6
Slide agglutination
A 0 0 0 0
B 8 0.7 5 0.7
C 1 0.1 0 0
E 1 0.1 1 0.1
W 0 0 0 0
X 1 0.1 0 0
Y 1 0.1 0 0
Z 0 0 0 0
NG 125 11.6 105 13.8
rt-PCR
A 0 0 0 0
B 19 1.8 20 2.6
C 2 0.2 2 0.3
W 0 0 0 0
X 2 0.02 2 0.3
Y 8 0.7 5 0.7
NG 106 9.9 82 10.8
Abbreviations: NG = Nongroupable, rt-PCR = real-time polymerase chain reaction.
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